Varenicline improves motor and cognitive symptoms in early Huntington’s disease

References

• PhillipsWShannonKMBarkerRAThe current clinical management of Huntington’s diseaseMov Disord200823111491150418581443
   PubMed Web of Science ®Google Scholar
• YouSCGeschwindMDShaSJExecutive functions in premanifest Huntington’s diseaseMov Disord201429340540924375511
   PubMed Web of Science ®Google Scholar
• MontoyaAPriceBHMenearMLepageMBrain imaging and cognitive dysfunctions in Huntington’s diseaseJ Psychiatry Neurosci2006311212916496032
   PubMed Web of Science ®Google Scholar
• NovakMJTabriziSJHuntington’s disease: clinical presentation and treatmentInt Rev Neurobiol20119829732321907093
   PubMed Web of Science ®Google Scholar
• van DuijnEKingmaEMTimmanRCross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington’s disease compared with mutation-negative first-degree relativesJ Clin Psychiatry200869111804181019026253
   PubMed Web of Science ®Google Scholar
• van DuijnEKingmaEMvan der MastRCPsychopathology in verified Huntington’s disease gene carriersJ Neuropsychiatry Clin Neurosci200719444144818070848
   PubMed Web of Science ®Google Scholar
• Van LiewCGluhmSGoldsteinJCronanTACorey-BloomJThe functional implications of motor, cognitive, psychiatric, and social problem-solving states in Huntington’s diseasePsychiatry201376432333524299091
   PubMed Web of Science ®Google Scholar
• ZanardiALeoGBiaginiGZoliMNicotine and neurodegeneration in ageingToxicol Lett20021271–320721512052660
   PubMed Web of Science ®Google Scholar
• PerryEKPerryRHSmithCJNicotinic receptor abnormalities in Alzheimer’s and Parkinson’s diseasesJ Neurol Neurosurg Psychiatry19875068068092956364
   PubMed Web of Science ®Google Scholar
• BatesGTabriziSJonesLHuntington’s Disease4th edOxford University PressOxford, UK2014
   Google Scholar
• WaldvogelHJKimEHTippettLJVonsattelJPFaullRLThe neuropathology of Huntington’s diseaseCurr Top Behav Neurosci201522338025300927
   PubMedGoogle Scholar
• SpokesEGNeurochemical alterations in Huntington’s chorea: a study of post-mortem brain tissueBrain198010311792106102490
   PubMed Web of Science ®Google Scholar
• LangeKWJavoy-AgidFAgidYJennerPMarsdenCDBrain muscarinic cholinergic receptors in Huntington’s diseaseJ Neurol199223921031041532417
   PubMed Web of Science ®Google Scholar
• FernandezHHFriedmanJHGraceJBeason-HazenSDonepezil for Huntington’s diseaseMov Disord200015117317610634264
   PubMed Web of Science ®Google Scholar
• RotUKobalJSeverAPirtosekZMesecARivastigmine in the treatment of Huntington’s diseaseEur J Neurol20029668969012453090
   PubMed Web of Science ®Google Scholar
• de TommasoMSpecchioNSciruicchioVDifruscoloOSpecchioLMEffects of rivastigmine on motor and cognitive impairment in Huntington’s diseaseMov Disord200419121516151815390067
   PubMed Web of Science ®Google Scholar
• CoeJWBrooksPRVetelinoMGVarenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessationJ Med Chem200548103474347715887955
   PubMed Web of Science ®Google Scholar
• TonstadSRollemaHVarenicline in smoking cessationExpert Rev Respir Med20104329129920524911
   PubMedGoogle Scholar
• ZesiewiczTASullivanKLTreatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14)Clin Neuropharmacol200831636336519050414
   PubMed Web of Science ®Google Scholar
• ZesiewiczTASullivanKLGoochCLLynchDRSubjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix)J Clin Neuromuscul Dis200910419119319494730
   PubMedGoogle Scholar
• ZesiewiczTAGreensteinPESullivanKLA randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3Neurology201278854555022323747
   PubMed Web of Science ®Google Scholar
• RollemaHGuanowskyVMineurYSVarenicline has antidepressant-like activity in the forced swim test and augments sertraline’s effectEur J Pharmacol20096051–311411619168054
   PubMed Web of Science ®Google Scholar
• ThomasKHMartinRMKnipeDWHigginsJPGunnellDRisk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysisBMJ2015350h110925767129
   PubMed Web of Science ®Google Scholar
• ObachRSReed-HagenAEKruegerSSMetabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitroDrug Metab Dispos200634112113016221753
   PubMed Web of Science ®Google Scholar
• MihalakKBCarrollFILuetjeCWVarenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptorsMol Pharmacol200670380180516766716
   PubMed Web of Science ®Google Scholar
• CiammolaASassoneJColciagoCAripiprazole in the treatment of Huntington’s disease: a case seriesNeuropsychiatr Dis Treat200951419557093
   PubMed Web of Science ®Google Scholar
• PaulRHLawrenceJWilliamsLMRichardCCCooperNGordonEPreliminary validity of “integneuro”: a new computerized battery of neurocognitive testsInt J Neurosci2005115111549156716223701
   PubMed Web of Science ®Google Scholar
• WilliamsLMSimmsEClarkCRPaulRHRoweDGordonEThe test-retest reliability of a standardized neurocognitive and neurophysiological test battery: “neuromarker”Int J Neurosci2005115121605163016287629
   PubMed Web of Science ®Google Scholar
• ClarkCRPaulRHWilliamsLMStandardized assessment of cognitive functioning during development and aging using an automated touchscreen batteryArch Clin Neuropsychol200621544946716904862
   PubMed Web of Science ®Google Scholar
• AndersonDJMalyszJGronlienJHStimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combinationBiochem Pharmacol200978784485119555668
   PubMed Web of Science ®Google Scholar
• EhretJCDayPSWiegandRWojcieszekJChambersRAHuntington disease as a dual diagnosis disorder: data from the national research roster for Huntington disease patients and familiesDrug Alcohol Depend2007862–328328616930866
   PubMed Web of Science ®Google Scholar
• BroseLSWestRStapletonJAComparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practiceMayo Clin Proc201388322623323489449
   PubMed Web of Science ®Google Scholar
• EbbertJOWyattKDHaysJTKleeEWHurtRDVarenicline for smoking cessation: efficacy, safety, and treatment recommendationsPatient Prefer Adherence2010435536221049087
   PubMed Web of Science ®Google Scholar
• RavvaPGastonguayMRFaesselHMLeeTCNiauraRPharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokersNicotine Tob Res201517110611325145377
   PubMed Web of Science ®Google Scholar
• ZigmondASSnaithRPThe hospital anxiety and depression scaleActa Psychiatr Scand19836763613706880820
   PubMed Web of Science ®Google Scholar
• BoraEVelakoulisDWalterfangMSocial cognition in Huntington’s disease: a meta-analysisBehav Brain Res201629713114026455876
   PubMed Web of Science ®Google Scholar
• LofflerLARadkeSMorawetzCDerntlBEmotional dysfunctions in neurodegenerative diseasesJ Comp Neurol201652481727174326011035
   PubMed Web of Science ®Google Scholar
• BaezSHerreraEGershanikOImpairments in negative emotion recognition and empathy for pain in Huntington’s disease familiesNeuropsychologia20156815816725582408
   PubMed Web of Science ®Google Scholar
• SilversteinSMJaegerJDonovan-LeporeAMA comparative study of the MATRICS and IntegNeuro cognitive assessment batteriesJ Clin Exp Neuropsychol201032993795220455131
   PubMed Web of Science ®Google Scholar
• MasonSLZhangJBegetiFThe role of the amygdala during emotional processing in Huntington’s disease: from pre-manifest to late stage diseaseNeuropsychologia201570808925700742
   PubMed Web of Science ®Google Scholar
• WallaceTLBertrandDImportance of the nicotinic acetylcholine receptor system in the prefrontal cortexBiochem Pharmacol201385121713172023628449
   PubMed Web of Science ®Google Scholar
• LogueSFGouldTJThe neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibitionPharmacol Biochem Behav2014123455423978501
   PubMed Web of Science ®Google Scholar
• NiemegeersPDumontGJQuisenaertsCThe effects of nicotine on cognition are dependent on baseline performanceEur Neuropsychopharmacol20142471015102324766971
   PubMed Web of Science ®Google Scholar
• LevinEDBradleyAAddyNSiguraniNHippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memoryNeuroscience2002109475776511927157
   PubMed Web of Science ®Google Scholar
• LevinEDalpha7-Nicotinic receptors and cognitionCurr Drug Targets201213560260622300026
   PubMed Web of Science ®Google Scholar
• QuikMZhangDPerezXABordiaTRole for the nicotinic cholinergic system in movement disorders; therapeutic implicationsPharmacol Ther20141441505924836728
   PubMed Web of Science ®Google Scholar